Dawn Peck

Dawn Peck

Auto-generated profile, based on publicly available information

Dawn Peck

Department of Genetics, University of Missouri in Columbia, 404 N Keene St, Suite 101, Columbia, MO 65201, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2018 in Brain
Verified
Journal Article
Open access
PDF file
KBKate Baker
Kate Baker
SGSarah L Gordon
Sarah L Gordon
HMHolly Melland
Holly Melland
FBFabian Bumbak
Fabian Bumbak
DSDaniel Scott
Daniel Scott
FRF Lucy Raymond
F Lucy Raymond
Synaptotagmin 1 (SYT1) is a critical mediator of fast, synchronous, calcium-dependent neurotransmitter release and also modulates synaptic vesicle endocytosis. This paper describes 11 patients with de novo heterozygous missense mutations in SYT1. All mutations alter highly conserved residues, and cluster in two regions of the SYT1 C2B domain at positions Met303 (M303K), Asp304 (D304G), Asp366 (D366E), Ile368 (I368T) and Asn371 (N371K). Phenotypic features include infantile hypotonia, congenital ophthalmic abnormalities, childhood-onset hyperkinetic movement disorders, motor stereotypies, and developmental delay varying in severity from moderate to profound. Behavioural characteristics include sleep disturbance and episodic agitation. Absence of epileptic seizures and normal orbitofrontal head circumference are important negative features. Structural MRI is unremarkable but EEG disturbance is universal, characterized by intermittent low frequency high amplitude oscillations. The functional impact of these five de novo SYT1 mutations has been assessed by expressing rat SYT1 protein containing the equivalent human variants in wild-type mouse primary hippocampal cultures. All mutant forms of SYT1 were expressed at levels approximately equal to endogenous wild-type protein, and correctly localized to nerve terminals at rest, except for SYT1M303K, which was expressed at a lower level and failed to localize at nerve terminals. Following stimulation, SYT1I368T and SYT1N371K relocalized to nerve terminals at least as efficiently as wild-type SYT1. However, SYT1D304G and SYT1D366E failed to relocalize to nerve terminals following stimulation, indicative of impairments in endocytic retrieval and trafficking of SYT1. In addition, the presence of SYT1 variants at nerve terminals induced a slowing of exocytic rate following sustained action potential stimulation. The extent of disturbance to synaptic vesicle kinetics is mirrored by the severity of the affected individuals’ phenotypes, suggesting that the efficiency of SYT1-mediated neurotransmitter release is critical to cognitive development. In summary, de novo dominant SYT1 missense mutations are associated with a recognizable neurodevelopmental syndrome, and further cases can now be diagnosed based on clinical features, electrophysiological signature and mutation characteristics. Variation in phenotype severity may reflect mutation-specific impact on the diverse physiological functions of SYT1.

1 May 2015 in Genetics in Medicine
Verified
Journal Article
Closed access
DLDawn A. Laney
Dawn A. Laney
DPDawn S. Peck
Dawn S. Peck
AAAndrea M. Atherton
Andrea M. Atherton
LMLinda P. Manwaring
Linda P. Manwaring
KCKatherine M. Christensen
Katherine M. Christensen
RHRobert J. Hopkin
Robert J. Hopkin

1 August 2018 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
MBMelissa M. Minter Baerg
Melissa M. Minter Baerg
SSStephanie D. Stoway
Stephanie D. Stoway
JHJeremy Hart
Jeremy Hart
LMLea Mott
Lea Mott
DPDawn S. Peck
Dawn S. Peck
PRPiero Rinaldo
Piero Rinaldo
The implementation of newborn screening for lysosomal disorders has uncovered overall poor specificity, psychosocial harm experienced by caregivers, and costly follow-up testing of false-positive cases. We report an informatics solution proven to minimize these issues. The Kentucky Department for Public Health outsourced testing for mucopolysaccharidosis type I (MPS I) and Pompe disease, conditions recently added to the recommended uniform screening panel, plus Krabbe disease, which was added by legislative mandate. A total of 55,161 specimens were collected from infants born over 1 year starting from February 2016. Testing by tandem mass spectrometry was integrated with multivariate pattern recognition software (Collaborative Laboratory Integrated Reports), which is freely available to newborn screening programs for selection of cases for which a biochemical second-tier test is needed. Of five presumptive positive cases, one was affected with infantile Krabbe disease, two with Pompe disease, and one with MPS I. The remaining case was a heterozygote for the latter condition. The false-positive rate was 0.0018% and the positive predictive value was 80%. Postanalytical interpretive tools can drastically reduce false-positive outcomes, with preliminary evidence of no greater risk of false-negative events, still to be verified by long-term surveillance.

5 June 2007 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
KGKaren Gripp
Karen Gripp
ALAngela E. Lin
Angela E. Lin
LNLinda Nicholson
Linda Nicholson
WAWilliam Allen
William Allen
ACAndrea Cramer
Andrea Cramer
KSKatia Sol‐Church
Katia Sol‐Church

20 December 2006 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
GSG. S. Salomons
G. S. Salomons
CJC. Jakobs
C. Jakobs
LPL. Landegge Pope
L. Landegge Pope
AEA. Errami
A. Errami
MPM. Potter
M. Potter
KGK. M. Gibson
K. M. Gibson

1 January 2013 in NeuroImage: Clinical
Verified
Journal Article
Open access
SCShawn E. Christ
Shawn E. Christ
AMAmanda J. Moffitt
Amanda J. Moffitt
DPDawn Peck
Dawn Peck
DWDesirée A. White
Desirée A. White
Phenylketonuria (PKU) is a rare genetic condition characterized by an absence or mutation of the PAH enzyme, which is necessary for the metabolism of the amino acid phenylalanine into tyrosine. Recently, sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4), has been introduced as a supplemental treatment to dietary phe control for PKU. Very little is known regarding BH4 treatment and its effect on brain and cognition. The present study represents the first examination of potential changes in neural activation in patients with PKU during BH4 treatment. To this end, we utilized an n-back working memory task in conjunction with functional magnetic resonance imaging (fMRI) to evaluate functional brain integrity in a sample of individuals with PKU at three timepoints: Just prior to BH4 treatment, after 4 weeks of treatment, and after 6 months of treatment. Neural activation patterns observed for the PKU treatment group were compared with those of a demographically-matched sample of healthy non-PKU individuals who were assessed at identical time intervals. Consistent with past research, baseline evaluation revealed impaired working memory and atypical brain activation in the PKU group as compared to the non-PKU group. Most importantly, BH4 treatment was associated with improvements in both working memory and brain activation, with neural changes evident earlier (4-week timepoint) than changes in working memory performance (6-month timepoint).